Evidence map›Paper›PMID 32149713›Full record

ArticleJournal of medical Internet research2020

The Interactive Web-Based Program MSmonitor for Self-Management and Multidisciplinary Care in Persons With Multiple Sclerosis: Quasi-Experimental Study of Short-Term Effects on Patient Empowerment.

Peter Joseph Jongen, Gezien Ter Veen, Wim Lemmens, Rogier Donders, Esther van Noort, Esther Zeinstra

Open access · goldAbstract read
In one paragraph

Article in Journal of medical Internet research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Medication self-management toolkits for adults with multiple sclerosis: A scoping review.Exploratory research in clinical and social pharmacy · 2023
    Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Peter Joseph JongenDepartment of Community and Occupational Medicine, University Medical Centre Groningen, University of Groningen, Groningen, Netherlands.ORCID 0000-0002-9202-6309
Gezien Ter Veen *Zorggroep Noorderboog, Meppel, Netherlands.ORCID 0000-0002-5565-156X
Wim LemmensRadboud University Medical Center, Department for Health Evidence, Nijmegen, Netherlands.ORCID 0000-0002-7159-0541
Rogier DondersRadboud University Medical Center, Department for Health Evidence, Nijmegen, Netherlands.ORCID 0000-0002-0484-1419
Esther van NoortCuravista bv, Geertruidenberg, Netherlands.ORCID 0000-0001-7142-1126
Esther ZeinstraIsala Hospital, Meppel, Netherlands.ORCID 0000-0002-2777-2313
Radboud University Nijmegen · NLIsala · NLUniversity Medical Center Groningen · NLZorggroep Meander · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEmpowerment helps persons with a chronic disease to self-manage their condition and increase their autonomy and participation. MSmonitor (Curavista bv) is an interactive Web-based program for self-management and multidisciplinary care in multiple sclerosis (MS). It includes, among others, short questionnaires on fatigue (Modified Fatigue Impact Scale-5 [MFIS-5]) and health-related quality of life (HRQoL, Leeds Multiple Sclerosis Quality of Life [LMSQoL]); long questionnaires on disabilities, perception of disabilities (Multiple Sclerosis Impact Profile), and HRQoL (Multiple Sclerosis Quality of Life-54); a Medication and Adherence Inventory and an Activity Diary. The combination MFIS-5, LMSQoL, and Medication and Adherence Inventory constitutes the Quick Scan.

objectiveThis study aimed to investigate the short-term effects of MSmonitor on empowerment in patients with MS.

methodsWe conducted a quasi-experimental study in a general hospital. Of the 180 patients with MS, 125 were eligible, 30 used MSmonitor, and 21 participated in the study (mean age 45.4 years, SD 10.2 years). A total of 24 eligible patients who did not use MSmonitor constituted the control group (mean age 49.3 years, SD 11.4 years). At baseline and at 4 months, we assessed self-efficacy (Multiple Sclerosis Self-Efficacy Scale [MSSES]), participation and autonomy (Impact on Participation and Autonomy [IPA] questionnaire), and self-management (Partners In Health [PIH] questionnaire). Differences between time points and groups were tested with paired t tests and χ² tests.

resultsIn the MSmonitor group, follow-up values remained unchanged for MSSES control (P=.19), MSSES function (P=.62), IPA limitations (P=.26), IPA problems (P=.40), PIH recognition and management of symptoms (P=.52), PIH adherence to treatment (P=.80), and PIH coping (P=.73), whereas the PIH knowledge score had improved (mean 27.8, SD 1.7 vs mean 28.7, SD 2.0; P=.02). The overall utilization rate of the program components was 83% and that of the Quick Scan was 95%. In the control group, all outcomes had remained unchanged.

conclusionsThe results suggest that for first-time users of the MSmonitor program and their health care providers, it may not be justified to expect a short-term improvement in empowerment in terms of self-efficacy, self-management, autonomy, or participation. Furthermore, a lack of effect on empowerment is not because of nonusage of the program components.

Indexed as

EmpowermentFemaleHumansInternetMaleMiddle AgedMultiple SclerosisNon-Randomized Controlled Trials as TopicQuality of LifeSelf-ManagementSurveys and QuestionnairesTelemedicineeHealthempowermentinternet-based communicationinternet-based interventionmultiple sclerosispersonal autonomyself-efficacyself-managementsocial participation

Identifiers

PMID32149713
PMCPMC7091023
OpenAlexW3012336789

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.